Thirty previously untreated patients with advanced measurable gastric cancer were given a combination chemotherapy consisting of 5-fluorouracil, 400 mg/m2, and leucovorin, 200 mg/m2 iv on days 1 to 3, mitomicyn-C, 10 mg/m2 on day 1 (every other cycle) and adriamycin, 40 mg/m2 on day 2, repeated every 21 days. The overall response rate was 46 % (14/30; 95 % confidence limits: 28 %-64 %) including 4 patients with a complete remission. Eight patients progressed. Median duration of remission (CR+PR) was 10 months, with a median survival of 13, 8 and 4 months for CR + PR, NC and PD, respectively. Main toxicities were leukopenia (WHO grade III-IV in 36 % of the patients) and alopecia. One patient died from myocardial infarction after an adriamycin cumulative dose of 480 mg/m2. No other treatment-related death occurred. L-FAM2 is an effective combination for advanced gastric carcinoma. Further studies based on the association of leucovorin and 5-fluorouracil in combination with other active drugs are warranted.
Get full access to this article
View all access options for this article.
References
1.
ArbukS.G.: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.Cancer, 63: 1036–1044, 1989.
2.
ArbukS.G., DouglassH.O., TraveF., MillronS., BaroniM., NavaH., RustumY.A.: A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.J. Clin. Oncol., 5: 1150–1156, 1987.
3.
ArbukS.G., DouglassH.O., NavaH., SilkY., RustumY.M.: A phase II trial of 5-FU, adriamycin, mitomycin-C and leucovorin (FAM-CF) in advanced gastric carcinoma.Proc. Am. Soc. Clin. Oncol., 8: 104 (abstract 402), 1989.
4.
ClarkP.I., SlevinM.L.: Allopurinol mouthwashes and 5-fluorouracil-induced oral toxicity.Eur. J. Surg. Oncol., 11: 267–268, 1985.
5.
CocconiG., BellaM.A., De LisiV.: La combinazione PELF nel carcinoma gastrico metastatizzato. In: Nuove prospettive in oncologia medica: l'associazione fluorouracile e folati.Di CostanzoF. (Ed.), pp. 117–122. Terni, 1990.
6.
DavisM., PritchardJ., AccettaP., MayE., TaxierM., RansbottomT., MillhonW.: Treatment of advanced gastric cancer with 5-FU, doxorubicin, cisplatin and folinic acid.Proc. Am. Soc. Clin. Oncol. (abstract 425), 9: 110, 1990.
Gastrointestinal Study Group: Triazinate and platinum efficacy in combination with 5-FU and doxorubicin. Results of a three arm randomized trial in metastatic gastric cancer.J.N.C.I., 80: 1011–1015, 1988.
9.
Gioffre FlorioM., FabianoV., MicaliB.: Il trattamento del carcinoma gastrico in fase avanzata con l'associazione sequenziale acido folinico e 5-fluorouracile.Farmaci Terapia, 4: 295–298, 1987.
10.
KelsenD., AtiqO., NiedzwieckiD., HoustonC.: A random assignment trial of fluorouracil (F), methotrexate (MTX), and adriamycin (A) (FAMTX) versus etoposide A and cisplatin (EAP) in gastric cancer (gast ca).Proc. Am. Soc. Clin. Oncol. (abstract 468), 9: 121, 1990.
11.
KlenH.O.: Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer.Anticancer Res., 9: 1025–1026, 1989.
MachoverD., GoldschmidtE., CholletP., MetzgerG., ZittounJ., MarquetJ., VandenbulckeJ.M., MissetJ.L., SchwarzembergL., FourtillanJ.B., GagetH., MathèG.: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.J. Clin. Oncol., 4: 685–696, 1986.
14.
PreusserP., WilkeH., AchterrathW., FinkU., LenazL., HeinickeA., MeyerJ., MeyerH.J., BuenteH.: Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer.J. Clin. Oncol., 7: 1310–1317, 1989.
15.
ScheinP.S.: The role of chemotherapy in the management of gastric and pancreatic carcinoma. Semin.Oncol., 4(Suppl 6): 49–60, 1985.
16.
WilkeH., PreusserP., FinkU., SthalM., SchmollH.J., LenazL., PoliwodaH.: High dose folinic acid/etoposide/5-FU in advanced gastric cancer: a phase II study in elderly patients or patients with cardiac risk.Invest. New Drugs, 8: 65–70, 1990.
17.
WilkeH., PreusserP., StahlM., FinkU., SchmollH.J., AchterrathW., LenazL., MeyerH.J., WegenerG., PoliwodaH.: Leucovorin/5-FU alone or in combination with other cytostatic drugs in the treatment of advanced gastric carcinoma. In: PinedoH.M., RustumY.M. (Eds.), pp. 87–95. Leucovorin modulation of flluoropyrimidines: a new frontier in cancer chemotherapy.Royal Society of Medicine Services.London-New York, 1989.
18.
WilsJ.A.: Current status of chemotherapy for advanced gastric cancer.Anticancer Res., 7: 755–760, 1987.
19.
WilsJ., KleinH.O., BuyseM., WagenerD.J., ReisH., DuezN.: FAMTX (5-FU, adriamycin, methotrexate): a step ahead in the treatment of advanced gastric cancer.Proc. Am. Soc. Clin. Oncol. (abstract 392), 9: 102, 1990.
20.
W.H.O.: Handbook for reporting results of cancer treatment. W.H.O. Offset publication N. 48. W.H.O., Geneva, Switzerland, 1979.
